Summit Therapeutics Inc. (SMMT) Financials
SMMT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-01-31 | 202.9 million | 125.3 million |
| 2023-10-31 | 218.5 million | 119.1 million |
| 2023-07-31 | 237.4 million | 117.8 million |
| 2023-04-30 | 254.9 million | 121.4 million |
SMMT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-01-31 | -19.5 million | 8.8 million |
| 2023-10-31 | -15.0 million | 705000 |
| 2023-07-31 | -29.3 million | 1.9 million |
| 2023-04-30 | -13.2 million | 2.8 million |
SMMT Net Income
No data available :(
SMMT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-01-31 | 186.2 million | - | - |
| 2023-10-31 | 198.9 million | - | 6.1 million |
| 2023-07-31 | 215.0 million | - | 6.7 million |
| 2023-04-30 | 241.9 million | - | 7.3 million |
SMMT Shares Outstanding
SMMT Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-01-31 | 2000 | 24.8 million | 11.6 million | - |
| 2023-10-31 | 53000 | 15.3 million | 5.4 million | - |
| 2023-07-31 | 20000 | 9.5 million | 6.3 million | - |
| 2023-04-30 | 53000 | 9.9 million | 6.9 million | - |
SMMT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-01-31 | - | 605000 |
| 2023-10-31 | - | 599000 |
| 2023-07-31 | 235000 | 471000 |
| 2023-04-30 | - | 375000 |
SMMT
Price: $4.40
52 week price:
Earnings Per Share: -0.99 USD
P/E Ratio: -3.76
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 252593
Ebitda: -3.9 millionMarket Capitalization: 2.8 billion